1. Ongoing partnership amendment for ABBV-230 with OSE Immunotherapeutics announced. 2. OSE regains early development control of ABBV-230, ensuring enhanced focus. 3. AbbVie retains rights for future development post-Phase 1 completion. 4. Existing commercial terms and royalty structures remain unchanged. 5. Collaboration reflects continued commitment to addressing chronic inflammation.
FAQ
Why Bullish?
The amendment enhances operational efficiency in early development, maintaining ABBV's competitive edge. Historical partnerships have shown that strategic control can positively influence market perception.
How important is it?
The article details a significant strategic shift, impacting ABBV's development lifecycle and market position. Such collaborations can lead to innovative breakthroughs, making it crucial for investors.
Why Long Term?
The strategic direction established now will influence ABBV's product pipeline and revenue for years. Previous examples of similar partnerships have led to successful product launches.
OSE Immunotherapeutics and AbbVie Amend Partnership on ABBV-230 Development
NANTES, France, December 8th, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has announced a strategic amendment to its partnership agreement with AbbVie concerning the development of ABBV-230, a monoclonal antibody aimed at resolving chronic and severe inflammation, currently in the pre-clinical development phase. This revised agreement is designed to enhance OSE Immunotherapeutics' role in the project while ensuring AbbVie's ongoing commitment to this innovative treatment.
Key Changes in the Partnership Agreement
The amended partnership agreement outlines a redistribution of development roles between OSE Immunotherapeutics and AbbVie:
- Early Development Leadership: OSE Immunotherapeutics will take charge of the preclinical and Phase 1 development of ABBV-230, leveraging its expertise in immunology. Financing for these activities will be conducted entirely by OSE Immunotherapeutics, subject to securing necessary funding.
- Continued AbbVie Rights: AbbVie retains exclusive licensing rights and will oversee future development and commercialization after the successful completion of Phase 1, maintaining its position as a leader in immunology.
- Unchanged Commercial Terms: All existing commercialization rights, including global net sales royalties and milestone payments, remain intact. OSE Immunotherapeutics will keep its full economic entitlements under the original agreement.
- Milestone Payment Adjustments: OSE Immunotherapeutics will not receive the previously anticipated milestone payment linked to the initiation of Phase 1. However, it will be eligible for milestone payments if AbbVie progresses ABBV-230 through subsequent developmental phases.
Significance of ChemR23 in Inflammation Resolution
ChemR23 is a dual-function receptor critical for managing inflammation, as it regulates immune cell recruitment and activity based on the ligand that binds to it. Both OSE Immunotherapeutics and AbbVie are committed to exploring its potential as a pioneering therapy for effective inflammation resolution.
CEO Insights on the Partnership
Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics, stated: “The overall value of our collaboration with AbbVie for ABBV-230 remains unchanged. By taking the lead on early-stage development, OSE can expedite the progress of this innovative program while utilizing our core expertise in immunology. This revised agreement reflects the value we’ve created together and our shared dedication to advancing transformative therapies for chronic inflammatory diseases.”
Background on the Partnership
The strategic partnership between OSE Immunotherapeutics and AbbVie was initially established to develop ABBV-230 in February 2024. This cooperation highlights the commitment of both companies to lead in the field of immunology and deliver groundbreaking solutions for serious medical conditions.
About OSE Immunotherapeutics
OSE Immunotherapeutics is a biotechnology firm focused on developing first-in-class assets in immuno-oncology and immuno-inflammation. The company collaborates with leading academic institutions and biopharmaceutical firms to create and provide transformative medicines for patients with serious diseases. Headquartered in Nantes and Paris, OSE Immunotherapeutics is listed on Euronext. Further information on OSE Immunotherapeutics and its assets can be found on the company's website: www.ose-immuno.com.